MAIA Biotechnology (MAIA) announced its entry into a clinical master supply agreement with Roche (RHHBY) for future studies. The agreement will investigate the combination of MAIA’s telomere-targeting agent ateganosine, sequenced with Roche’s checkpoint inhibitor atezolizumab, for the treatment of multiple hard-to-treat cancers. MAIA Chairman and CEO Vlad Vitoc stated that preclinical studies found ateganosine to be highly synergistic with atezolizumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Enters Inducement Offer Agreements
- MAIA Biotechnology Reports Positive Phase 2 Trial Results
- MAIA Biotechnology announces new partial response in Phase 2 THIO-101 trial
- MAIA Biotechnology announces updated data from THIO-101 trial
- MAIA Biotechnology Showcases Promising THIO-101 Trial Data